Tuesday, October 4, 2022


Biotechnology News Magazine

Cell Guidance Systems & Manchester BIOGEL Collaborate

To launch PODS-PeptiGels for 3D cell culture

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Cell Guidance Systems Ltd, a specialist in the control, manipulation, and monitoring of cells, both in vitro and in vivo, and Manchester BIOGEL, a biotechnology company specializing in the design and manufacture of 3D synthetic peptide hydrogels, today announced a collaboration to launch PODS®-PeptiGels®.

The new kit combines the benefits of two existing innovative cell culture technologies – synthetic peptide hydrogels (PeptiGels) and a range of sustained-release growth factors (PODS) – to provide a reproducible and highly adaptable environment for 3D cell culture.

PODS-PeptiGels incorporates Cell Guidance Systems’ POlyhedrin Delivery System (PODS) and Manchester BioGel’s biologically relevant hydrogels (PeptiGels). The ready-to-use kit allows researchers to mix and match to suit the aims of their research by selecting from more than 70 growth factors and combining with hundreds of combinations of hydrogels, each with mechanical and biomimetic tuneability.

Providing researchers with an all-in-one, animal-free, solution for 3D cell culture applications, the PeptiGel hydrogel, available in a variety of gel stiffness and cell adhesion motifs, is produced using synthetic peptides reducing batch variations and enables reproducible results. The PODS crystal protects the growth factor cargo allowing sustained release over a longer period, thereby reducing the frequency of media changes required and minimising growth factor concentration cycles.

Dr. Michael Jones, CEO of Cell Guidance Systems, commented: “We are excited to launch PODS-PeptiGels with Manchester BIOGEL. Combining the benefits of PeptiGel and PODS technologies provides researchers with a simple and repeatable, physiologically relevant, cell-matrix that produces consistent results in addition to reducing hands-on time.”

Dr. Donald Daley, CEO of Manchester BIOGEL, said: “Batch-to-batch variation of hydrogels is a big issue and our synthetic PeptiGels overcome this by eliminating variation making it easier to compare results. PeptiGels are functionalized synthetic platforms that support cell growth and are also free from animal origin. This combined with recombinant growth factors that do not degrade quickly due to the PODS technology from Cell Guidance Systems, makes for a powerful 3D cell culture solution that can be scaled up to high throughput, if required, whilst producing consistent and accurate results.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine